Aiforia Lung Cancer Suite

Aiforia® Lung Cancer Suite is a clinical AI solution designed to support pathologists in the diagnosis and biomarker assessment of lung cancer. The suite addresses one of the most pressing challenges in oncology pathology: the subjective, time-consuming, and variability-prone process of manual PD-L1 scoring, which directly influences immunotherapy treatment decisions for patients with lung cancer.

PD-L1 expression is a critical biomarker used to guide immunotherapy in lung cancer care. Even small discrepancies in scoring — as little as 5 to 10 percentage points — can shift a patient's entire treatment regimen. Under-calling PD-L1 expression can deny patients access to effective immunotherapy, while over-calling can lead to unnecessary treatment. Aiforia® Lung Cancer Suite applies AI-driven analysis to bring objectivity, reproducibility, and efficiency to this high-stakes diagnostic task.

Core AI Solution: Aiforia® Lung Cancer PD-L1

• Automatically detects invasive carcinoma in whole slide images (WSIs) and delivers standardized, reproducible tumor proportion scoring (TPS)
• Applies consistent AI-driven criteria to every slide, eliminating the variability introduced by visual estimation
• Examines every tumor cell across the entire slide — potentially hundreds or thousands of cells — ensuring comprehensive analysis
• Scores PD-L1 in minutes once trained, significantly accelerating turnaround times and freeing pathologists from tedious manual counting

Clinical Performance Highlights

• Excellent diagnostic accuracy with high correlation to expert visual assessments
• Enhanced consistency through improved pathologist concordance, with a Fleiss' Kappa of approximately 0.87
• Significantly streamlined workflow, reducing reporting time by up to 46%
• Reliable and standardized scoring at critical clinical thresholds, including the 1% and 50% cut-offs

Key Platform Capabilities

• Precise, transparent AI results: Aiforia goes beyond standard AI heatmaps by clearly marking exact tumor areas with detailed visual overlays directly on digital slides, enabling easy visual confirmation at any magnification level
• Quantitative and visual insights: Pathologists receive both visual transparency and exact quantitative data, including accurate tumor area measurements and cell counts, delivering actionable diagnostic insights
• Case-level review and reporting: Aiforia® Clinical Suites combine results from multiple AI models, WSIs, and stainings into a unified case-level view and report, supporting first-read diagnostic workflows
• Workflow acceleration: AI results are populated directly into the reporting panel, with advanced features including case list triaging, pre-ordering of extra stains, and flagging of non-representative samples
• Increased reliability of PD-L1 analysis: Standardized scoring with high accuracy reduces inter-observer variability and supports more consistent patient care decisions

Real-World Evidence and Resources

• A case study from University Hospital Southampton documents the implementation of Aiforia's clinical PD-L1 lung cancer AI solution for assessing PD-L1 staining in lung cancer specimens
• Educational webinar content covers real-world diagnostic pressure points of PD-L1 TPS testing in non-small cell lung cancer (NSCLC), including cut-offs, cognitive bias, and the role of AI

Aiforia® Lung Cancer PD-L1 is CE-IVD marked for diagnostic use in EU and EEA countries, and is available for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas. The solution integrates with a range of digital slide scanners and is designed to fit into existing pathology workflows in clinical, academic, and research settings.